SFA Therapeutics, Inc. Press releases
Oct 28, 2019
SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC).
Oct 25, 2019
Will Report on Clinical Development Plans for Multiple Promising Therapeutics Derived from Human Microbiome
Oct 18, 2019
Will Present Clinical Development Plans For Several Novel Therapeutic Agents Derived from Human Microbiome